First Implant Approved for Wet Macular Degeneration First Implant Approved for Wet Macular Degeneration
For the first time, an implant for age-related macular degeneration won approval from the FDA.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

FDA approves Roche ’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 22 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo ™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.1,2,3,4 Susvimo, previously called Port Delivery System with ranibizum...
Source: Roche Media News - October 22, 2021 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 22 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo ™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.1,2,3,4 Susvimo, previously called Port Delivery System with ranibizum...
Source: Roche Investor Update - October 22, 2021 Category: Pharmaceuticals Source Type: news

DNA in Cell Cytoplasm Implicated in Age-Related Blindness
A new study suggests that DNA synthesized in the cell cytoplasm drives retinal cell death in an advanced form of age-related macular degeneration, a leading cause of blindness. (Source: The Scientist)
Source: The Scientist - September 29, 2021 Category: Science Tags: News & Opinion Source Type: news

Millions with eye conditions at higher risk of dementia, shows research
People with macular degeneration, cataracts and diabetes-related eye disease at greater riskMillions of people with eye conditions including age-related macular degeneration, cataracts and diabetes-related eye disease have an increased risk of developing dementia, new research shows.Vision impairment can be one of the first signs of the disease, which is predicted to affect more than 130 million people worldwide by 2050.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 13, 2021 Category: Science Authors: Andrew Gregory Health editor Tags: Medical research Health Dementia Blindness and visual impairment Society Source Type: news

AbbVie and REGENXBIO Announce Eye Care Collaboration
AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other ch... Biopharmaceuticals, Regenerative Medicine, Ophthalmology AbbVie, REGENXBIO, gene therapy, macular degeneration, diabetic retinopathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 13, 2021 Category: Pharmaceuticals Source Type: news

Artificial Intelligence-Based Predictions in Neovascular AMD Artificial Intelligence-Based Predictions in Neovascular AMD
What role could artificial intelligence have in the clinical management of neovascular age-related macular degeneration?Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 3, 2021 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Bayer Middle East brings Alleye home monitoring programme to Egypt
The German pharma giant is working with top eye hospitals in the country to support virtual care for patients with Diabetic Macular Edema or age-related macular degeneration. (Source: mobihealthnews)
Source: mobihealthnews - September 3, 2021 Category: Information Technology Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growt...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growt...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news

FDA Accepts Application for Genentech ’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
South San Francisco, CA -- July 28, 2021 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA),... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 28, 2021 Category: Drugs & Pharmacology Source Type: news

FDA accepts application for Roche ’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 24 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). Neovascular AMD is a leading cause of blindness for people aged 60 and over and impacts approximatel y 20 million people worldwide.1,2,3 If approved, PDS would be a first-of-its-kind therapeutic approach, offering people living with nAMD an alternative to frequent eye i...
Source: Roche Investor Update - June 24, 2021 Category: Pharmaceuticals Source Type: news

FDA accepts application for Roche ’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 24 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). Neovascular AMD is a leading cause of blindness for people aged 60 and over and impacts approximatel y 20 million people worldwide.1,2,3 If approved, PDS would be a first-of-its-kind therapeutic approach, offering people living with nAMD an alternative to frequent eye i...
Source: Roche Media News - June 24, 2021 Category: Pharmaceuticals Source Type: news

Recycling of the eye's light sensors is faulty in progressive blindness of older adults
(University of Maryland School of Medicine) With the National Eye Institute reporting that about 11 million older adults in the U.S. endure a condition that leads to progressive blindness, known as age-related macular degeneration, University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in the disease, in order to develop new therapies to treat it. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 23, 2021 Category: International Medicine & Public Health Source Type: news

Scientists unravel the function of a sight-saving growth factor
(NIH/National Eye Institute) Researchers at the National Eye Institute (NEI) have determined how certain short protein fragments, called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye. The peptides might someday be used to treat degenerative retinal diseases, such as age-related macular degeneration (AMD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 16, 2021 Category: International Medicine & Public Health Source Type: news

A frozen leap forward
(University of California - Santa Barbara) Scientists at UC Santa Barbara, University of Southern California (USC) and biotechnology company Regenerative Patch Technologies LLC (RPT) have reported new methodology for preservation of RPT's stem cell-based therapy for age-related macular degeneration (AMD). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 14, 2021 Category: Biology Source Type: news

Does age-related macular degeneration (AMD) treatment influence patient falls and mobility? A systematic review - Garrigan H, Hamati J, Lalakia P, Frasso R, Salzman B, Hyman L.
PURPOSE: Age-related macular degeneration (AMD), a leading cause of irreversible blindness, increases fall risk through impaired central vision. Falls place an enormous economic burden on healthcare systems. We hypothesized that AMD treatments may reduce p... (Source: SafetyLit)
Source: SafetyLit - May 20, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Photobiomodulation Therapy in ARMD Photobiomodulation Therapy in ARMD
Is photobiomodulation therapy an effective treatment option for exudative and nonexudative AMD?Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 5, 2021 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
SEATTLE, April 7, 2021 -- (Healthcare Sales & Marketing Network) -- LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced positive findings in its LIGHTSIT... Devices, Ophthalmology LumiThera , photobiomodulation, Age-Related Macular Degeneration (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 7, 2021 Category: Pharmaceuticals Source Type: news

Lab model offers hope for macular degeneration patients
(University of Rochester) University of Rochester researchers have created a 3D lab model using patient-derived tissues that mimics the areas of the retina affected in age-related macular degeneration (AMD), which affects an estimated 196 million people. They believe this could lead to finding specific drugs for individual patients to treat a disease that currently has no cure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2021 Category: International Medicine & Public Health Source Type: news

Gene therapy trial for age-related macular degeneration now open at Columbia
(Columbia University Irving Medical Center) A clinical trial to test a gene therapy for some patients with dry age-related macular degeneration -- a leading cause of blindness in the United States -- is underway at Columbia and NewYork-Presbyterian. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2021 Category: International Medicine & Public Health Source Type: news

New Hope for Better Macular Degeneration Treatments
A number of new treatments for age-related macular degeneration (AMD), a progressive eye disease, are under development. (Source: WebMD Health)
Source: WebMD Health - February 22, 2021 Category: Consumer Health News Source Type: news

New Hope for Better Treatments Against Macular Degeneration
MONDAY, Feb. 22, 2021 -- A number of new treatments for age-related macular degeneration (AMD), a progressive eye disease, are under development. AMD is a leading cause of vision loss in older people. About 11 million Americans have AMD, which... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 22, 2021 Category: General Medicine Source Type: news

New phase III data show Roche ’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients
Basel, 12 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular or “wet” age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up to four months, offered non-inferior vision gains compared to aflibercept, given every two months. Approximately half of people eligible for extended dosing with faricimab were able to be treated every four months in the first year in the YOSEMITE and ...
Source: Roche Investor Update - February 12, 2021 Category: Pharmaceuticals Source Type: news

New phase III data show Roche ’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients
Basel, 12 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular or “wet” age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up to four months, offered non-inferior vision gains compared to aflibercept, given every two months. Approximately half of people eligible for extended dosing with faricimab were able to be treated every four months in the first year in the YOSEMITE and ...
Source: Roche Media News - February 12, 2021 Category: Pharmaceuticals Source Type: news

Ambient Air Pollution Tied to Age-Related Macular Degeneration Ambient Air Pollution Tied to Age-Related Macular Degeneration
People with higher exposure to ambient air pollution are at increased risk for age-related macular degeneration and changes in retinal thickness, a UK study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Air Pollution May Up Risk for Age-Related Macular Degeneration
WEDNESDAY, Jan. 27, 2021 -- Greater exposure to fine ambient particulate matter with an aerodynamic diameter
Source: Drugs.com - Pharma News - January 27, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Roche ’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration
Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, in people living with neovascular or “wet” age-related macular degeneration (nAMD). Both studies met their primary endpoint and showed that people receiving faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes that were non-inferior to those receiving aflibercept injections every eight wee ks. Nearly half (45%) of people in both stud...
Source: Roche Investor Update - January 25, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration
Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, in people living with neovascular or “wet” age-related macular degeneration (nAMD). Both studies met their primary endpoint and showed that people receiving faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes that were non-inferior to those receiving aflibercept injections every eight wee ks. Nearly half (45%) of people in both stud...
Source: Roche Media News - January 25, 2021 Category: Pharmaceuticals Source Type: news

Air pollution linked to higher risk of sight loss from AMD
(University College London) Air pollution is linked to a heightened risk of progressive and irreversible sight loss, known as age related macular degeneration (AMD), reveals a large long term study led by UCL researchers, published in the British Journal of Ophthalmology. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 25, 2021 Category: International Medicine & Public Health Source Type: news

Roche ’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness
Basel, 21 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks. Faricimab was generally well-tolerated, with no new safety signals identified. The studies each h...
Source: Roche Media News - December 21, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness
Basel, 21 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks. Faricimab was generally well-tolerated, with no new safety signals identified. The studies each h...
Source: Roche Investor Update - December 21, 2020 Category: Pharmaceuticals Source Type: news

Development of the first biohybrid artificial retina built with silk fibroin and retinal cells.
(Universidad Complutense de Madrid) An international research led by the Complutense University of Madrid has taken a further step to solve Age-related Macular Degeneration (AMD)-derived blidness problem with the development of the first biohybrid artificial retina built with silk fibroin and retinal cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news

New insights about age-related macular degeneration could spur better treatments
(Massachusetts General Hospital) Experiments in a mouse model have uncovered mechanisms involved in abnormal blood vessel formation in " wet " age-related macular degeneration. Certain inflammatory pathways and proteins may be attractive therapeutic targets for the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news

Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration
RARITAN, NJ, December 2, 2020 – Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced the acquisition of rights to Hemera Biosciences, LLC’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD). Financial terms of the transaction with Hemera Biosciences, a privately-owned biotechnology company, are not being disclosed. Patients with AMD often have low levels of CD59, a prote...
Source: Johnson and Johnson - December 2, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Ranibizumab Biosimilar Shows Equivalent Efficacy to Branded Drug for Neovascular AMD Ranibizumab Biosimilar Shows Equivalent Efficacy to Branded Drug for Neovascular AMD
In a phase 3 study, the ranibizumab biosimilar SB11 demonstrated equivalent efficacy and similar safety and immunogenicity profiles compared with ranibizumab for patients with neovascular age-related macular degeneration (nAMD).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 1, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa
RARITAN, N.J., November 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new 12-month data from the ongoing Phase 1/2 trial (NCT03252847) of its investigational gene therapy for inherited retinal disease X-linked retinitis pigmentosa (XLRP). The data showed that low and intermediate doses were well-tolerated and continued to demonstrate statistically significant sustained or increased vision improvement across multiple metrics (mean sensitivity, volumetric and pointwise) and modalities (full-field static perimetry and microperimetry). Data on the novel adeno-associated virus re...
Source: Johnson and Johnson - November 13, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Vitamin D3, Omega-3 Fatty Acids Have No Impact on AMD
FRIDAY, Oct. 30, 2020 -- For initially healthy men and women, supplementation with vitamin D3 and marine omega-3 fatty acids have no significant impact on age-related macular degeneration (AMD) incidence or progression, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 30, 2020 Category: Pharmaceuticals Source Type: news

Anti-VEGF Therapy May Aid Visual Acuity in Some nAMD Patients
MONDAY, Oct. 19, 2020 -- For about 20 percent of patients with neovascular age-related macular degeneration (nAMD), useful visual acuity (VA) is preserved with anti-vascular endothelial growth factor (VEGF) treatment, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 19, 2020 Category: Pharmaceuticals Source Type: news

For Some, Anti-VEFG Treatment Preserves Sight for a Lifetime For Some, Anti-VEFG Treatment Preserves Sight for a Lifetime
Nearly 20% of those who received anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) retained useful visual acuity over their lifetime, a new study finds.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 17, 2020 Category: Pathology Tags: Ophthalmology News Source Type: news

Changes to Anti-VEGF Protocols Questioned in Wet AMD Changes to Anti-VEGF Protocols Questioned in Wet AMD
New research calls into question the benefit of newer injection schedules to prevent vision loss in neovascular age-related macular degeneration.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 14, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Implant Reduces Treatment Burden in Wet Macular Degeneration Implant Reduces Treatment Burden in Wet Macular Degeneration
The administration of ranibizumab with an implant, rather than intravitreal injection, looks promising for neovascular age-related macular degeneration, interim results from a phase 3 study indicate.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 13, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Visible Genomics hires clinical advisers to prep for macular degeneration test
The company is preparing to launch a non-invasive genetic eye test that can determine a patient's likelihood of contracting age-related macular degeneration. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 28, 2020 Category: Biotechnology Authors: I-Chun Chen Source Type: news

Parkinson's Drug Levodopa Eyed as Treatment for Severe Macular Degeneration
WEDNESDAY, Sept. 16, 2020 -- A drug long used to treat Parkinson's disease may benefit patients with a severe form of age-related macular degeneration (AMD), a small clinical trial suggests. One of the leading causes of vision loss in older people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 16, 2020 Category: General Medicine Source Type: news

Levodopa Benefits Neovascular Age-Related Macular Degeneration
TUESDAY, Sept. 15, 2020 -- Levodopa is a safe and well-tolerated treatment for neovascular age-related macular degeneration (nAMD) and improves visual outcomes, according to a study recently published in The American Journal of Medicine. Anna G.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2020 Category: Pharmaceuticals Source Type: news

Levodopa may improve vision in patients with macular degeneration
(Elsevier) Investigators have determined that treating patients with an advanced form of age-related macular degeneration (AMD) with levodopa, a safe and readily available drug commonly used to treat Parkinson's disease, stabilized and improved their vision. It reduced the number of treatments necessary to maintain vision, and as such, will potentially reduce the burden of treating the disease, financially and otherwise. Their findings appear in The American Journal of Medicine, published by Elsevier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

RegenxBio is growing — and pushing its eye disease treatment through yet another clinical trial
The Rockville biotech is trying to change the game for patients with wet age-related macular degeneration and diabetic retinopathy. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 27, 2020 Category: Biotechnology Authors: Sara Gilgore Source Type: news

Artificial intelligence recognizes deteriorating photoreceptors
(University of Bonn) A software based on artificial intelligence (AI), which was developed by researchers at the Eye Clinic of the University Hospital Bonn, Stanford University and University of Utah, enables the precise assessment of the progression of geographic atrophy (GA), a disease of the light sensitive retina caused by age-related macular degeneration (AMD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2020 Category: International Medicine & Public Health Source Type: news

Phase III data show Roche ’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
Basel, 22 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.1 In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care. In the study, PDS was generally well-tolerated, with a favourable benefit...
Source: Roche Media News - July 22, 2020 Category: Pharmaceuticals Source Type: news